Goldman Sachs’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-42,922
| Closed | -$79.4K | – | 6266 |
|
|
2023
Q1 | $79.4K | Sell |
42,922
-83,824
| -66% | -$104K | ﹤0.01% | 5485 |
|
|
2022
Q4 | $141K | Sell |
126,746
-34,773
| -22% | -$49.5K | ﹤0.01% | 5403 |
|
|
2022
Q3 | $378K | Sell |
161,519
-43,114
| -21% | -$153K | ﹤0.01% | 5160 |
|
|
2022
Q2 | $620K | Sell |
204,633
-187,283
| -48% | -$911K | ﹤0.01% | 4929 |
|
|
2022
Q1 | $2.66M | Sell |
391,916
-328,529
| -46% | -$2.34M | ﹤0.01% | 3972 |
|
|
2021
Q4 | $6.02M | Buy |
720,445
+46,519
| +7% | +$383K | ﹤0.01% | 3233 |
|
|
2021
Q3 | $5.01M | Buy |
673,926
+509,577
| +310% | +$3.16M | ﹤0.01% | 3363 |
|
|
2021
Q2 | $1.12M | Buy |
164,349
+13,038
| +9% | +$108K | ﹤0.01% | 4680 |
|
|
2021
Q1 | $1.55M | Buy |
151,311
+115,764
| +326% | +$1.27M | ﹤0.01% | 4244 |
|
|
2020
Q4 | $249K | Sell |
35,547
-2,540
| -7% | -$19.8K | ﹤0.01% | 4979 |
|
|
2020
Q3 | $310K | Sell |
38,087
-18,785
| -33% | -$116K | ﹤0.01% | 4721 |
|
|
2020
Q2 | $392K | Sell |
56,872
-23,090
| -29% | -$125K | ﹤0.01% | 4501 |
|
|
2020
Q1 | $380K | Sell |
79,962
-31,004
| -28% | -$178K | ﹤0.01% | 4374 |
|
|
2019
Q4 | $969K | Sell |
110,966
-25,823
| -19% | -$140K | ﹤0.01% | 4152 |
|
|
2019
Q3 | $456K | Buy |
136,789
+43,114
| +46% | +$173K | ﹤0.01% | 4499 |
|
|
2019
Q2 | $464K | Buy |
93,675
+3,374
| +4% | +$17.9K | ﹤0.01% | 4431 |
|
|
2019
Q1 | $560K | Sell |
90,301
-4,921
| -5% | -$23.8K | ﹤0.01% | 4370 |
|
|
2018
Q4 | $321K | Sell |
95,222
-6,516
| -6% | -$30.4K | ﹤0.01% | 4598 |
|
|
2018
Q3 | $661K | Buy |
101,738
+17,742
| +21% | +$132K | ﹤0.01% | 4267 |
|
|
2018
Q2 | $643K | Buy |
83,996
+7,216
| +9% | +$104K | ﹤0.01% | 4362 |
|
|
2018
Q1 | $1.72M | Buy |
76,780
+14,993
| +24% | +$333K | ﹤0.01% | 3702 |
|
|
2017
Q4 | $788K | Sell |
61,787
-53,175
| -46% | -$782K | ﹤0.01% | 4483 |
|
|
2017
Q3 | $1.79M | Buy |
114,962
+45,314
| +65% | +$641K | ﹤0.01% | 4094 |
|
|
2017
Q2 | $977K | Buy |
69,648
+57,336
| +466% | +$1.23M | ﹤0.01% | 4485 |
|
|
2017
Q1 | $271K | Buy |
+12,312
| New | +$261K | ﹤0.01% | 5537 |
|
Other funds holding JNCE
Goldman Sachs's JNCE Position: Q2 2023 in Review
Goldman Sachs sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 42,922 shares — an estimated $79.4K sold.
Goldman Sachs first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $6.02M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Goldman Sachs reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Goldman Sachs sold 42,922 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $79.4K.
- Goldman Sachs first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Goldman Sachs's Jounce Therapeutics, Inc. Common Stock position peaked at $6.02M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.